Soc. Generale Call 1300 Novo-Nord.../ DE000SY2CAZ8 /
16/08/2024 08:45:37 | Chg.0.000 | Bid09:50:09 | Ask09:50:09 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.100EUR | 0.00% | 0.098 Bid Size: 60,000 |
0.110 Ask Size: 60,000 |
- | 1,300.00 DKK | 20/12/2024 | Call |
GlobeNewswire
28/06
SNIPR Biome receives funding for the development of CRISPR-medicines to improve Environmental Enteri...
GlobeNewswire
24/06
Veru Announces Safety and Body Composition Data from Two Late-Breaker Presentations at the American ...
GlobeNewswire
18/06
Novo Nordisk announces presentation of data from key semaglutide clinical trials in diabetes, obesit...
GlobeNewswire
18/06
Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for ...
GlobeNewswire
17/06
Veru Reminds Shareholders to Vote in Advance of Tomorrow’s Deadline for 2024 Annual Meeting of Share...
GlobeNewswire
13/06
Aeterna Zentaris Announces Last Patient Last Visit in Pivotal DETECT-Trial for the Diagnosis of Chil...
GlobeNewswire
11/06
Biora Therapeutics Announces Presentation on the BioJet™ Systemic Oral Delivery Platform at the Next...
GlobeNewswire
10/06
RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships
GlobeNewswire
31/05
Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia...
GlobeNewswire
30/05
Anaqua Annual User Experience Conference to Feature Keynotes from Microsoft, SAP, USPTO, and More
GlobeNewswire
15/05
Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Cl...